

## Special Issue

# New Insights into Connective Tissue Disorders

### Message from the Guest Editor

Dramatic advances in the management of rheumatoid arthritis and other autoimmune diseases are ongoing. The earliest possible diagnosis and active intervention are recommended, with the goal of inducing and maintaining remission. Currently, many types of drugs targeting T and B cells, innate immune cells, inflammatory cytokines, and JAKs are available, but treatment efficacy varies due to the heterogeneity of the diseases. Composite measures are useful for validating disease activity, since specific, single biomarkers are not known. A prominent feature of autoimmune diseases is the production of autoantibodies and autoreactive T cells. The target antigens of specific autoantibodies have been identified for several autoimmune diseases, but the related pathogenesises are mostly unknown. Also, their links to innate immune cascades and therapies still need to be clarified. The aim of the Special Issue is to highlight new developments in our understanding of connective tissue diseases, including their diagnosis, treatment, biomarkers, pathogenesis, and molecular mechanisms. The articles focusing on human immunology and its connective tissue disorders are welcome.

### Guest Editor

Prof. Dr. Isao Matsumoto

Division of Rheumatology, Department of Internal Medicine, University of Tsukuba, Tsukuba, Japan

### Deadline for manuscript submissions

closed (15 January 2022)



## Journal of Clinical Medicine

an Open Access Journal  
by MDPI

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/73408](https://mdpi.com/si/73408)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
jcm](https://mdpi.com/journal/jcm)



## About the Journal

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67000  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).